<DOC>
	<DOCNO>NCT02534363</DOCNO>
	<brief_summary>Cognitive enhancement primary goal treat individual schizophrenia . Cognitive deficit already present first break illness , seem remain stable early phase noticeably influence daily functioning . Differences among antipsychotic term cognitive effectiveness turn topic increase research interest . The initially postulate superior neurocognitive effectiveness second-generation antipsychotic ( SGAs ) compare first-generation antipsychotic ( FGAs ) currently debate . Long-term study would great value evaluate differential benefit exert antipsychotic drug cognitive performance . The aim study investigate cognitive effect aripiprazole , quetiapine ziprasidone first-episode psychosis 1 year .</brief_summary>
	<brief_title>Neurocognitive Effectiveness Treatment First-episode Non-affective Psychosis : 1-year Follow-up</brief_title>
	<detailed_description>Study set financial support : data present investigation obtain ongoing epidemiological three-year longitudinal intervention program first-episode psychosis ( PAFIP ) conduct outpatient clinic inpatient unit University Hospital Marqu√©s de Valdecilla , Spain . Conforming international standard research ethic , program approve local institutional review board . Patients meet inclusion criterion family provide write informed consent include PAFIP . The Mental Health Services Cantabria provide fund implement program . No pharmaceutical company supply financial support . Study design : prospective , randomize , flexible-dose , open-label study . Investigators use simple randomization procedure : computer-generated randomization list drawn statistician . Dose range 5-30 mg/day Aripiprazole , 40-160 mg/day Ziprasidone 100-600 mg/day Quetiapine . Rapid titration schedule ( 5-day ) , optimal dose reach , rule use unless severe side effect occur . At treat physician 's discretion , dose type antipsychotic medication could change base clinical efficacy profile side effect follow-up period . Antimuscarinic medication , Lormetazepam Clonazepam permit clinical reason . No antimuscarinic agent administer prophylactically . Antidepressants ( Sertraline ) mood stabilizer ( lithium ) permit clinically need . Clinical assessment : severity scale Clinical Global Impression ( CGI ) scale , Brief Psychiatric Rating Scale ( BPRS ) , Scale Assessment Positive symptom ( SAPS ) , Scale Assessment Negative symptom ( SANS ) , Calgary Depression Scale Schizophrenia ( CDSS ) Young Mania Rating Scale ( YMRS ) use evaluate symptomatology . To assess general adverse event experience , Scale Udvalg Kliniske Undersogelser ( UKU ) , Simpson-Angus Rating Scale ( SARS ) Barnes Akathisia Scale ( BAS ) use . The trained psychiatrist ( BC-F ) complete clinical assessment . These clinical data describe AZQ2005 study . Neuropsychological assessment . Cognitive functioning assess patient 2 point : baseline 1 year initialization antipsychotic treatment . The cognitive assessment baseline carry 12 week recruitment time consider optimal patient ' stabilization . The evaluation require approximately 2 h carry day neuropsychologist ( R.A.-A E.G.-R ) . The neuropsychological battery comprise 9 cognitive domain : information processing speed , motor dexterity , work memory , verbal learning , visuospatial ability , delayed memory , attention , executive function theory mind .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients follow First Episode Psychosis Clinical Program ( PAFIP II ) October 2005 January 2011 . Experiencing first episode psychosis ( First Episode Psychosis define psychopathological state first time regardless duration , patient enough severe psychotic symptom allow diagnosis psychosis , receive specific psychiatric treatment ) . Living catchment area ( Cantabria ) . No prior treatment antipsychotic medication , previously treat , total life time adequate antipsychotic treatment le 6 week . Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria brief psychotic disorder , schizophreniform disorder , schizophrenia , schizoaffective disorder . Meeting DSMIV criterion drug dependence . Meeting DSMIV criterion mental retardation . Having history neurological disease head injury loss consciousness .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cognition</keyword>
	<keyword>Psychosis</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Treatment</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Ziprasidone</keyword>
	<keyword>Neurocognition</keyword>
</DOC>